Compounds and preparations having antiviral effect

Details Compounds and preparations having antiviral effect Compounds and preparations having antiviral effect

2003-05-22

2010-02-16

Hui, San-ming (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C554S229000, C568S664000

Reexamination Certificate

active

07662852

ABSTRACT:
An antiviral preparation comprising as an active ingredient, a phorbol derivative of formula 1:wherein is R1is —(CH2)aX(CH2)bCH3, —(CH2)cX(CH2)dYCH3, —CO(CH2)eCH3or —(CH2)fCH3R2is —CO(CH2)nCH3, R3, R4and R5are hydrogen atom, or an aliphatic or aromatic carboxylic acid residue, X and Y are O or S, and each of a-f and n is a number, and having a specific safety index S.I.=CC50/EC50of 10 or more wherein EC50means a concentration at which HIV-1 induced cytopathogenic effect (CPE) in MT-4 cell is inhibited by 50%, and CC50means a concentration at which survival of MT-4 cell in a cell proliferation test is reduced by 50%. These preparations are particularly effective for human immuno-deficiency virus (HIV).

REFERENCES:
patent: 6268395 (2001-07-01), Hattori
patent: A-05-097888 (1993-04-01), None
patent: A-05-279329 (1993-10-01), None
patent: A-05-331067 (1993-12-01), None
patent: A-06-025158 (1994-02-01), None
patent: A-06-056825 (1994-03-01), None
patent: A-06-073004 (1994-03-01), None
patent: A-06-234641 (1994-08-01), None
patent: A-06-316524 (1994-11-01), None
patent: A-07-082292 (1995-03-01), None
patent: A-07-285877 (1995-10-01), None
patent: A-09-030974 (1997-02-01), None
patent: A-11-322789 (1999-11-01), None
patent: WO 01/82927 (2001-11-01), None
Raffanti S and Haas DW, Chapter 51 Antimicrobial Agents, “Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th ed.” Hardman JG, Limbird LE, and Goodman AG, Eds., McGraw-Hill, New York, 2001.
Carey FA and Sundberg RJ, Chapter 13, Section 13.1, “Advanced Organic Chemistry 3rd. Ed.”, Plenum Press, New York, 1990, pp. 678-686 provided.
Greene TW and Wuts PGM, “Protective Groups in Organic Synthesis,” John Wiley & Sons, Inc., New York, 1991, Chapter 2, pp. 10-13, 88, and 89 provided.
El-Mekkawy et al., “Inhibition of Cytopathic Effect of Human Immunodeficiency Virus Type-1 by Various Phorbol Derivatives,” Chem. Pharrn. Bull., 2002, vol. 50, No. 4, pp. 523-529.
El-Mekkawy et al., “12-O-Acetylphorbol-13-decanoate Potently Inhibits Cytopathic Effects of Human Immunodeficiency Virus Type 1 (HIV-1), without Activation of Protein Kinase C,” Chem. Pharm. Bull., 1999, vol. 47, No. 9, pp. 1346-1347.
El-Mekkawy et al., “Anti-HIV-1 phorbol esters from the seeds ofCroton tiglium,” Phytochemistry, 2000, vol. 53, No. 4, pp. 457-464.
Maio et al., “Regulation of Expression Driven by Human Immunodeficiency Virus Type 1 and Human T-Cell Leukemia Virus Type 1 and Human T-Cell Leukemia Virus Type I Long Terminal Repeats in Pluripotential Human Embryonic Cells,” J. Virol., 1988, vol. 62, No. 4, pp. 1398-1407.
Kinzel et al., “Stimulation of Choline Incorporation in Cell Cultures by Phorbol Derivatives and Its Correlation with Their Irritant and Tumor-Promoting Activity,” Cancer Research, 1979, vol. 39, No. 7, pp. 2743-2750.
Chem. Abstr., vol. 70, No. 4, 1969, pp. 359-360, abstract No. 70: 47626, Kreibich et al. “Chemistry of Phorbol. V. Phorbol Ethers,” Chemie, Biochemie. Biophysik. Biologie., 1968, vol. 23, No. 11, pp. 1444-1452.

Affiliated with

Also associated with

Rating

Compounds and preparations having antiviral effect does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds and preparations having antiviral effect, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and preparations having antiviral effect will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4192758